Objective: There is no strong evidence to guide therapeutic approach to multiple myeloma (MM) patients who experience first relapse. The treatment choice can be difficult since currently all patients are exposed to novel agents as thalidomide, bortezomib and lenalidomide. Methods: In this retrospective analysis, we evaluated the best therapeutic sequence, the role of retreatment, and the most beneficial cutoff of first remission in order to choose retreatment, analyzing 476 patients relapsed after first-line therapy. Results: Bortezomib-based regimens upfront followed by lenalidomide-based regimens at first relapse resulted in significantly better second progression-free survival (2ndPFS), PFS2, and overall survival (OS) compared to the opposite sequence. Changing therapy resulted in significantly better 2ndPFS in the whole population, whereas PFS2 was significantly longer only in patients who underwent maintenance therapy. Moreover, until PFS1 was shorter than 27 months, changing therapy at first relapse significantly extended 2ndPFS and PFS2 compared to retreatment, whereas similar outcomes were observed between the two strategies, when PFS1 was longer than 27 months. Conclusion: Lacking randomized trials, our study could help to choose the most appropriate therapy algorithm in patients with MM.
In the last few years, progression-free survival (PFS) and overall survival (OS) have significantly improved in patients with newly diagnosed multiple myeloma (MM) due to the availability of new effective drugs, such as thalidomide, bortezomib, and lenalidomide, and the improved supportive care (1, 2) . Yet, the majority of MM patients eventually relapse. Relapsed-refractory MM outcome has improved after the introduction of novel combinations such as lenalidomide-dexamethasone (Rd) (3, 4) , bortezomibdexamethasone (VD) (5) (6) (7) (8) , and bortezomib-doxorubicin (V-doxo) (9) . However, there are no clear recommendations about the choice of salvage therapy, although one randomized study conducted in the relapse setting, demonstrated the superiority of the triplet bortezomibthalidomide-dexamethasone (VTD) over the doublet thalidomide-dexamethasone (TD) (10) . Moreover, most of the patients enrolled in the registrational studies above (3, 4, 9, 11) received old drugs upfront, while currently, all patients are exposed to novel agents thalidomide, lenalidomide, and bortezomib.
The therapeutic approach to first relapse is outstandingly important. Indeed, at this stage, therapy can still have a substantial impact on outcome. Nevertheless, the selection of therapy in this setting is mainly empirical. Up to now, the toxicity and the efficacy of upfront therapies are considered the key factors to decide whether to treat patients with the same drug used at diagnosis or to change class of drug. To better evaluate the impact of first-and second-line therapies on the outcome, the European Medicines Agency (12) recommended to include PFS2, defined as the time from random assignment until the second disease progression or death, as an endpoint in clinical trials. Since it is unlikely that randomized clinical trials will be performed to establish the best strategy in first relapse, a careful analysis of recent salvage therapies used in clinical practice in patients previously exposed to new drugs will provide a valid guide to physicians.
In this retrospective study, we compared the results obtained with several combinations in a large population of patients with relapsed MM. Our aim was to address some burning questions such as the best therapy sequence and rechallenge with previous therapy vs. changing strategies.
Patients and methods

Patient population
Patients with MM enrolled in two phase III prospective trials [bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide (VMPT-VT) vs. bortezomibmelphalan-prednisone (VMP; NCT01063179); and melphalan-prednisone-lenalidomide (MPR) vs. high-dose melphalan (Mel-200) and transplantation (NCT00551928)] relapsed after first-line therapy and who underwent first salvage therapy were analyzed.
Study design
This is a retrospective study approved by Local Ethics Committee. Data about salvage therapies in patients at first relapse enrolled in the VMPT-VT vs. VMP and in the MPR vs. Mel-200 studies were collected. The aims were to describe and compare salvage therapies at first relapse, to analyze the best sequence of first/second-line therapy, to assess rechallenge with previous therapy vs. change of treatment in terms of second PFS, PFS2, and OS. Moreover, we tried to find the most beneficial duration of PFS1 to choose retreatment instead of changing therapy.
Definitions
Second PFS (2ndPFS) was defined as the time between start of first salvage therapy and confirmed progressive disease (PD) or death from any cause.
PFS2 was defined as the time from random assignment to the date of confirmed PD or death from any cause after second-line therapy.
OS was defined as the time from random assignment to death from any cause and postrelapse OS was defined as the time from start of second-line therapy to death from any cause.
Statistical analysis
Continuous and categorical data were summarized using descriptive statistics. Comparisons between groups were conducted with chi-square test for contingency table for categorical variables and with Mann-Whitney U-test for continuous variables. The Kaplan-Meier product limit method was used to estimate survivorship functions for time-to-event endpoints (2ndPFS, PFS2 and OS). Log-rank test was used to compare survival outcomes between the treatment groups. Assuming that changing therapy was better than retreatment, we empirically searched for the cutoff of PFS1 duration that was able to abrogate the significant advantage of changing therapy by evaluating three-month increments of PFS1 duration from 12 to 27 months.
SPSS System version 20 (SPPS Science, Chicago, IL, USA) was used for all statistical analyses.
Results
All population
We analyzed 476 patients who relapsed after first-line therapy consisting in VMP (n = 152), VMPT-VT (n = 105), MPR (n = 80), MPR-R (n = 52), Mel-200 (n = 48), and Mel-200-R (n = 39). Characteristics of these six treatments groups are described in the Table 1 . These patients underwent first salvage therapies including bortezomib (n = 136), lenalidomide (n = 142), thalidomide (n = 36), chemotherapy (n = 63), autologous stem-cell transplant (ASCT; n = 92), and allogeneic transplant (n = 7). In the whole population, after a median follow-up of 51 months (range 0.7-81.5), median 2ndPFS, PFS2, and OS were 14 (95% CI = 11.8-16.1), 39.8 (95% CI = 36.8-42.9), and 71 (95% CI = 57-NR) months, respectively. 
Myeloma subtype IgA heavy chain, n (%)
40 (26) 29 (28) 11 (14) 10 (19) 7 (14.5) 9 (23) International Staging System III, n (%)
31 (20) 17 (16) 17 (21) 15 (29) 16 (33) 10 (28) High risk cytogenetics 1 , n (%)
29 (19) 24 (23) 17 (21) 14 (27) 14 (29) 5 (13) Karnofsky score ≤70%, n (%)
36 (24) 35 (33) 16 (20) 10 (19) 7 (14.5)
19 (12.5) 9 (8.5) 11 (14) 5 (10) 7 (14.5) 5 (13) 1
Defined by the presence of t(4;14) and/or del(17p).
Subgroup analysis according to salvage therapies
Of 257 patients not eligible for transplantation, 15% received bortezomib (2ndPFS = 8.8 months), 50% lenalidomide (2ndPFS = 16.6 months), 12% thalidomide (2ndPFS = 8.6 months), and 21% chemotherapy (2ndPFS = 6.6 months) as salvage therapy at first relapse.
Out of 219 younger patients eligible for transplantation, 44% received salvage therapy with bortezomib (2ndPFS = 7.2 months), 7% immunomodulatory drugs (IMiDs; 2ndPFS = 14.3 months), 41.5% bortezomib followed by ASCT (2ndPFS = 21.5 months), and 3% allogeneic transplant (2ndPFS = 35.7 months).
Subgroup analysis according to sequence of therapy
Fifty-six patients received lenalidomide-based induction followed by ASCT as frontline therapy and bortezomib-based regimen at first relapse (L-B group), whereas 130 patients received the opposite sequence, that is, bortezomib-based frontline therapy followed by lenalidomide-based regimen at first relapse (B-L group). Patients who underwent ASCT as salvage therapy were excluded from the analysis. The two groups of patients were matched for the main characteristics as shown in the Table 2 .
The median 2ndPFS was 7.2 months in the L-B group vs. 16.6 months in the B-L group (P < 0.0001), whereas the respective median PFS2 was 36.6 months vs. 51.7 months (P < 0.0001; Fig. 1A ). The median OS was 45 months in the L-B group and 62.3 months in B-L group, with a fiveyear OS of 50% vs. 65% (P = 0.015; Fig. 1B ). The outcome of these two groups of patient, split for maintenance therapy or not, is shown in the Table 3 .
Subgroup analysis according to rechallenge vs. change of therapy Out of 476 patients, 311 could be included in the analysis of rechallenge with previous therapy (group R) vs. therapy change (group C). Patients who received bortezomib-or lenalidomide-based treatment followed by transplantation were excluded from analysis. Group R included 52 patients (17%; 37 patients received bortezomib-based and 15 lenalidomide-based treatments), whereas group C included Defined by the presence of t(4;14) and/or del(17p). In the whole population, the median 2ndPFS and PFS2 were 23.1 and 39.0 months, respectively. The median 2ndPFS was 8.8 months in group R compared to 12.7 months in group C (P = 0.038; Fig 2A) . The median PFS2 was 39.9 months in group R compared to 38.8 months in group C (P = 0.584; Fig. 2B ). Excluding the only 7 primary refractory patients, the results did not change (data not shown).
There was no significant difference in the survival parameters between retreatment with bortezomib-or with lenalidomide-based therapy (data not shown).
Second PFS was significantly longer in the group C compared to group R both in patients on maintenance therapy (23.1 months vs. 10.4 months; P = 0.045) or not (13.5 months vs. 8.7 months; P = 0.030), whereas PFS2 was significantly better in the group C compared to group R only in patients on maintenance therapy (63.1 months vs. 38.4 months; P = 0.031). Patients not receiving maintenance therapy, PFS2 resulted 39.6 months in group C vs. 38.5 in group R (P = 0.756).
Considering the PFS1 duration cutoffs mentioned above, we found a significant advantage in group C as PFS1 was ≤27 months (2ndPFS 10.2 months vs. 5.3 months; P = 0.006 and PFS2 29 vs. 24 months, P = 0.0080). On the contrary, in patients with PFS1 longer than 27 months, 2ndPFS (16.6 months vs. 16.3 months, P = 0.614) and PFS2 (38.6 months vs. 39.8 months; P = 0.584) became similar between the two therapeutic options (Fig. 3A-D) .
Discussion
Although many newer second-generation antimyeloma agents have been evaluated for relapsed-refractory MM, in many European countries, nowadays, thalidomide-, lenalidomide-and bortezomib-based therapies are still used in clinical practice in first relapse (13) .
The first two lines of therapy are considered of paramount importance for the final outcome of MM since generally, at this stage, the disease is still sensitive to therapy, leading to longer remission duration. Nonetheless, the sequence of therapy could significantly affect PFS2, which considers the outcome of first-and second-line therapy. Our study suggested that bortezomib-based therapies in first line followed by R, patients retreated with the same agent used as induction; C, patients who changed therapy. 1 Defined by the presence of t(4;14) and/or del(17p). lenalidomide-based therapies in second line significantly prolonged 2ndPFS and PFS2 compared to the opposite sequence. This finding applies either in patients receiving and not receiving maintenance therapy. However, we were aware of the heterogeneity of the patients and treatments considered in this study (i.e., no elderly patients received continuous lenalidomide plus dexamethasone, and no younger patients underwent bortezomib followed by transplantation in first line). The FIRST trial (14) demonstrated that elderly patients treated with continuous lenalidomidedexamethasone obtained a similar PFS compared to those patients receiving bortezomib-melphalan-prednisone, although head to head comparison was not performed. In light of these features, future studies will be able to advise the best sequence that should be used in elderly patients.
No treatment can be currently considered standard of care in relapsed MM and the choice of appropriate therapy is based on several factors, particularly outcome and toxicity of first-line treatment. When a patient relapses, the very first step is to decide whether this patient can undergo retreatment with the same agent, and in which combination can be a valid therapeutic option.
Our study showed that, in first relapse, physicians prefer to change the class of new drugs. Indeed, less than 20% of patients received the same compound administered upfront. Moreover, although guidelines suggest using retreatment with previous agent when remission duration is longer than 6 months, this strategy is mainly adopted with remission lasting more than 24 months. Our results demonstrated that changing therapy could be the preferable strategy as it significantly prolonged 2ndPFS and PFS2, especially in patients receiving maintenance therapy as well as in patients with PFS1 duration up to 27 months. On the contrary, in patients not receiving maintenance therapy and in those with PFS1 longer than 27 months, the two strategies (rechallenge with previous agents or changing therapy) seem to be equivalent. Our results support the concept that, in first relapse, rechallenge with previous agents is a sensible choice when PFS1 is longer than expected and not based on a priori established PFS1 duration. Moreover, sequential strategies with new drugs used in the earlier phases of the disease showed to be more effective, because drug resistance is unlikely to emerge in these stages.
Some studies evaluated retreatment with bortezomib or lenalidomide in relapsed/refractory MM. The prospective phase 2 RETRIEVE study (15) demonstrated the efficacy of rechallenging with bortezomib (AEdexamethasone) in patients who had previously responded to prior bortezomib therapy and relapsed ≥6 months after this therapy. The median time from prior bortezomib was 13.9 months and the median TTP was not affected by the number of prior lines of therapy (8.4 months in patients who had received one prior therapy). Similar results were reported in a meta-analysis in relapsed and not refractory patients, where retreatment with bortezomib induced a median TTP of 8.5 months (16). Our results are comparable to those reported in the previous studies (median 2ndPFS: 8.8 months). Rechallenge with lenalidomide is a possible option as well, as shown in a post hoc analysis of relapsed patients enrolled in the MM-015 trial (17) .
Recent biological studies (18) (19) (20) on MM demonstrated a complex clonal heterogeneity at diagnosis and an unpredictable clonal evolution at relapse due to clonal competition in the marrow niche that may be strongly affected by prior therapies. Because of this unpredictable complexity, the choice of therapy at relapse is quite empirical. By definition, empirical therapy should be a broad-spectrum therapy and this consideration suggests that triplets may work better than doublets. Only one randomized study compared two-drug (TD) vs. three-drug regimens (VTD) in first relapse (10) and it demonstrated a significantly longer PFS in patients treated with triplet combination. However, 80% of patients enrolled in that study had never received new drugs and the remaining 20% had received thalidomide. Therefore, such results are poorly informative in clinical practice, since nowadays all patients are exposed to bortezomib-or lenalidomide-based therapies. Recent randomized studies, in patients with relapsed-refractory MM treated with 1-3 prior lines of therapy, demonstrated that, adding the third drug such as carfilzomib, ixazomib, elotuzumab, daratumumab, and panobinostat to the backbone regimens such as lenalidomide-dexamethasone (21-24) and bortezomib-dexamethasone (25, 26) , response rate and 2ndPFS were significantly better compared to the backbones. The differences in favor of triplet therapies were particularly significant in first relapse (21, 23, 24) . Therefore, these new regimens will modify the modality of treatment of MM patients in first relapse when they will be widely available in clinical practice.
In conclusion, our post hoc analysis suggests that retreatment with previous agents should be considered when PFS1 is longer than what was expected with the regimen administered and in patients without maintenance therapy. Bortezomib-based therapy upfront followed by lenalidomidebased salvage therapy at first relapse seems to be the most effective approach although this claim could be denied by recent findings in elderly patients. Since it is unlikely that randomized studies will be performed to answer the above questions, our results can be a valid help in the everyday clinical practice to choose the most appropriate therapy algorithm pending new combinations including secondgeneration new drugs in first line and in relapsed-refractory MM.
